Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Oncgnostics Cervical Cancer Assay Receives Extended CE-IVD Mark

Oncgnostics Cervical Cancer Assay Receives Extended CE-IVD Mark

Feb 26, 2019
|
staff reporter

 

NEW YORK (GenomeWeb) – Oncgnostics announced recently that it has received an extended CE-IVD mark for the GynTect cervical cancer assay. As a result, researchers can run the assay on Roche Diagnostics' Cobas z 480 quantitative PCR-based analyzer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

What's Popular?

In Cancer

  1. Local Coverage Determinations Roundup: CareDx, Castle Bio, Decipher Biosciences

  2. Oncocyte DetermaRx Predicts Early Lung Cancer Outcomes Regardless of EGFR Status

    Premium

  3. Genetron Health Licenses ImmuQuad Technology for Blood Cancer Testing

  4. CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.